Edoxaban was noninferior to warfarin in preventing stroke or systemic embolism, with significantly lower rates of bleeding and cardiovascular death.
Does edoxaban prevent stroke or systemic embolism in patients with atrial fibrillation compared to warfarin?
Once-daily edoxaban is noninferior to warfarin for stroke prevention in atrial fibrillation and reduces the risk of bleeding and cardiovascular death.
Tasa de eventos absoluta: 0% vs 0%
Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.).
Giugliano et al. (Tue,) reported a other. Edoxaban was noninferior to warfarin in preventing stroke or systemic embolism, with significantly lower rates of bleeding and cardiovascular death.